Innova Captab Ltd
Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain.[1]
- Market Cap ₹ 4,304 Cr.
- Current Price ₹ 752
- High / Low ₹ 1,021 / 608
- Stock P/E 54.0
- Book Value ₹ 148
- Dividend Yield 0.27 %
- ROCE 11.6 %
- ROE 11.6 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE 1000
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|
| 373 | 411 | 785 | 859 | 865 | 958 | 1,183 | |
| 322 | 356 | 687 | 760 | 755 | 836 | 1,044 | |
| Operating Profit | 51 | 54 | 99 | 99 | 110 | 122 | 139 |
| OPM % | 14% | 13% | 13% | 11% | 13% | 13% | 12% |
| 1 | 1 | 3 | 9 | 9 | 17 | 17 | |
| Interest | 5 | 4 | 5 | 18 | 14 | 2 | 13 |
| Depreciation | 10 | 6 | 7 | 11 | 11 | 17 | 36 |
| Profit before tax | 38 | 46 | 89 | 78 | 94 | 120 | 107 |
| Tax % | 26% | 26% | 25% | 26% | 27% | 25% | |
| 28 | 34 | 66 | 58 | 68 | 89 | 80 | |
| EPS in Rs | 232.42 | 287.50 | 551.50 | 11.99 | 11.91 | 15.63 | 13.92 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 7% |
| TTM: | 29% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 11% |
| TTM: | -13% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -15% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | 14% |
| Last Year: | 12% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 12 | 12 | 48 | 57 | 57 | 57 |
| Reserves | 98 | 133 | 199 | 220 | 666 | 756 | 791 |
| 54 | 45 | 176 | 237 | 244 | 329 | 318 | |
| 81 | 178 | 157 | 173 | 187 | 223 | 277 | |
| Total Liabilities | 245 | 368 | 544 | 678 | 1,155 | 1,365 | 1,443 |
| 73 | 79 | 161 | 161 | 164 | 637 | 653 | |
| CWIP | 0 | 7 | 0 | 22 | 339 | 21 | 7 |
| Investments | 0 | 0 | 60 | 60 | 60 | 60 | 60 |
| 172 | 282 | 322 | 435 | 593 | 647 | 723 | |
| Total Assets | 245 | 368 | 544 | 678 | 1,155 | 1,365 | 1,443 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 31 | 42 | 58 | 39 | 112 | 20 | |
| -6 | -20 | -188 | -88 | -472 | -100 | |
| -23 | -19 | 125 | 51 | 368 | 84 | |
| Net Cash Flow | 1 | 3 | -5 | 3 | 8 | 4 |
| Free Cash Flow | 27 | 23 | -21 | -39 | -165 | -141 |
| CFO/OP | 79% | 101% | 80% | 59% | 123% | 32% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 85 | 123 | 81 | 98 | 92 | 95 |
| Inventory Days | 84 | 107 | 63 | 67 | 68 | 94 |
| Days Payable | 92 | 132 | 84 | 102 | 111 | 119 |
| Cash Conversion Cycle | 77 | 99 | 60 | 63 | 49 | 70 |
| Working Capital Days | 45 | 39 | 23 | 44 | 58 | 65 |
| ROCE % | 28% | 33% | 21% | 15% | 12% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio (FATR) - Standalone Base x |
|
||||
| Installed Capacity - Capsules Million Units |
|||||
| Installed Capacity - Tablets Million Units |
|||||
| Net Working Capital Days Days |
|||||
| Actual Production - Capsules Million Units |
|||||
| Actual Production - Tablets Million Units |
|||||
| CDMO Customers Count Units |
|||||
| Export Presence (Count of Countries) Units |
|||||
| Number of CDMO Products Sold Units |
|||||
| Indian Formulation CDMO Market Share % |
|||||
| Pharmacy Touchpoints in India Units |
|||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
30 Apr - The Company has scheduled meet of Analysts/ Investors (Participants) to discuss the Audited Financial Results for the quarter and financial year ended 31st March, 2026, …
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
29 Apr - Filed Annual Secretarial Compliance Report for year ended 31 March 2026.
-
Board Meeting Intimation for Intimation Of Board Meeting Under Regulations 29 Of The SEBI (LODR) Regulations, 2015 For Consideration Of Audited (Standalone And Consolidated) Financial Results For The Quarter And Financial Year Ended 31St March, 2026.
29 Apr - Board meeting on 7 May 2026 to approve audited Q4 and FY2026 standalone and consolidated results.
-
Announcement under Regulation 30 (LODR)-Credit Rating
14 Apr - CARE reaffirmed Innova Captab’s ratings on ₹466.72 crore facilities on 14 April 2026, with positive outlook.
-
Intimation Under Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirement) Regulations, 2015
14 Apr - Shimla GST SCN proceedings dropped on 14 Apr 2026; ₹15.81 crore demand and penalties waived.
Concalls
-
Feb 2026TranscriptPPT
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT REC
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT REC
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT REC
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024Transcript PPT
Business Profile[1]
Innova Captab Limited is an integrated pharmaceutical player with a strong presence across the pharmaceutical value chain